Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.

Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management

Abstract

Frontotemporal lobar degeneration (FTLD) describes a spectrum of clinically, pathologically and genetically heterogeneous neurodegenerative disorders of unknown aetiology. FTLD spectrum disorders collectively represent a leading cause of early-onset dementia, with most cases presenting between 45 and 64 years of age. FTLD is characterized by progressive changes in behaviour, executive dysfunction and/or language impairment and can be differentiated clinically into three frontotemporal dementia (FTD) syndromes as follows: (i) behavioural variant (bvFTD); (ii) semantic dementia (SD); and (iii) progressive nonfluent aphasia (PNFA). Additionally, there is a significant clinical, pathological and genetic overlap between FTD and motor neuron disease/amyotrophic lateral sclerosis (FTD-ALS) and the atypical parkinsonian syndromes, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). bvFTD is characterized by progressive behavioural impairment and a decline in executive function with frontal lobe-predominant atrophy, SD by a loss of object knowledge with prominent anomia and asymmetrical atrophy of the anterior temporal lobes and PNFA by expressive or motor speech deficits with predominantly left peri-sylvian atrophy. Recent advances in molecular biology and immunohistochemical staining techniques have further classified the FTLD spectrum disorders based upon the predominant neuropathological protein into three main categories: (i) microtubule-associated protein tau (FTLD-TAU); (ii) TAR DNA-binding protein-43 (FTLD-TDP); and (iii) fused in sarcoma protein (FTLD-FUS). Up to 40% of FTD patients report a family history of neurodegenerative illness, and one-third to one-half of familial cases of FTD follow an autosomal dominant inheritance pattern. Mutations in MAPT, PGRN, TARDBP, VCP and CHMP2B have been described, along with a recently identified C9ORF72 hexanucleotide repeat expansion. To date, there are no US FDA-approved treatments or disease-modifying therapies for FTD. Pharmacological strategies have focused on neurotransmitter replacement and modulation for the treatment of behavioural, motor and cognitive symptoms of FTD, and include selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, acetylcholinesterase inhibitors and glutamate NMDA receptor antagonists. At present, adequate management of FTD symptoms involves a combination of pharmacological therapy with behavioural, physical and environmental modification techniques.

Overview

Integrity signals

Registry

Crossref · 10.2165/11640070-000000000-00000

Cites

223 of 223 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 223 references

Research works printed but not linked: 9

  1. Pick, 1892, Prager Med Wochenschr, 17, 165
  2. Rascovsky, 2005, Neurology, 58, 1802
  3. Cardarelli, 2010, Am Fam Physician, 82, 1372
  4. Belfor, 2004, Neurology, 62, A237
  5. Feany, 1995, Am J Pathol, 146, 1388
  6. Rohrer, 2011, Brain, 134, 2565, 10.1093/brain/awr198 · DOI · Paper page
  7. He, 1999, Cancer Res, 59, 3222
  8. Ishii, 1998, J Nucl Med, 39, 1875
  9. Sperfeld, 1999, Ann Neurol, 46, 708, 10.1002/1531-8249(199911)46:5<708::aid-ana5>3.0.co;2-k · doi:10.1002/1531-8249(199911)46:5<708::aid-ana5>3.0.co;2-k

Cited by

See all 160

Metadata

Authors
Seltman, R. E., & Matthews, B. R.
Affiliations
Indiana University School of Medicine (US)
Corresponding author
Matthews, Brandy R.
Venue
CNS Drugs
Published
2012-10
Volume
26
Issue
10
Pages
841-870
ISSN
1172-7047 (ISSN-L)
OpenAlex
W1605023419
Cited by
132
References
223
Citations by year
2026: 2 · 2025: 4 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 10 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 8 · 2016: 20 · 2015: 17 · 2014: 13 · 2013: 12 · 2012: 1
FWCI
1.85
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P30AG010133)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
frontotemporal lobar degeneration, frontotemporal dementia, behavioral variant frontotemporal dementia, semantic dementia, progressive nonfluent aphasia, progressive supranuclear palsy, corticobasal syndrome, tauopathy, TDP-43, FUS, genetic mutations, C9orf72 repeat expansion, early-onset dementia, executive dysfunction, language impairment, pharmacotherapy, acetylcholinesterase inhibitors, NMDA receptor antagonists, atypical antipsychotics, selective serotonin reuptake inhibitors
MeSH terms
Humans, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management. https://app.cochat.ai/papers/10.2165/11640070-000000000-00000
The paper
Seltman, R. E., & Matthews, B. R. (2012). Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management. CNS Drugs. https://doi.org/10.2165/11640070-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.